NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial ; volume:15 ; number:1 ; day:13 ; month:12 ; year:2023 ; pages:1-15 ; date:12.2023
Alzheimer's research & therapy ; 15, Heft 1 (13.12.2023), 1-15, 12.2023

Creator: Sosa, Saily
Bringas, Giosmany
Urrutia, Nelky
Peñalver, Ana Ivis
López, Danay
González, Evelio
Fernández, Ana
Hernández, Zenaida Milagros
Viña, Ariel
Peña, Yamile
Batista, Juan Felipe
Valenzuela, Carmen
León, Kalet
Crombet, Tania
Rodríguez, Teresita
Pérez, Leslie

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13195-023-01356-w

URN: urn:nbn:de:101:1-2024022810221305899257

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Sosa, Saily
Bringas, Giosmany
Urrutia, Nelky
Peñalver, Ana Ivis
López, Danay
González, Evelio
Fernández, Ana
Hernández, Zenaida Milagros
Viña, Ariel
Peña, Yamile
Batista, Juan Felipe
Valenzuela, Carmen
León, Kalet
Crombet, Tania
Rodríguez, Teresita
Pérez, Leslie
SpringerLink (Online service)

Other Objects (12)

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Alzheimer’s Disease: Epidemiology and Clinical Progression

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease

Drug candidates in clinical trials for Alzheimer’s disease

Imaging endpoints for clinical trials in Alzheimer’s disease

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease

Predicting early Alzheimer’s with blood biomarkers and clinical features

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

Retinal tissue hypoperfusion in patients with clinical Alzheimer’s disease

Attitudes toward clinical trials across the Alzheimer’s disease spectrum

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Alzheimer’s Disease: Epidemiology and Clinical Progression

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease

Drug candidates in clinical trials for Alzheimer’s disease

Imaging endpoints for clinical trials in Alzheimer’s disease

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease

Predicting early Alzheimer’s with blood biomarkers and clinical features

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

Retinal tissue hypoperfusion in patients with clinical Alzheimer’s disease

Attitudes toward clinical trials across the Alzheimer’s disease spectrum

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Alzheimer’s Disease: Epidemiology and Clinical Progression

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease

Drug candidates in clinical trials for Alzheimer’s disease

Imaging endpoints for clinical trials in Alzheimer’s disease

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease

Predicting early Alzheimer’s with blood biomarkers and clinical features

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

Retinal tissue hypoperfusion in patients with clinical Alzheimer’s disease

Attitudes toward clinical trials across the Alzheimer’s disease spectrum

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Alzheimer’s Disease: Epidemiology and Clinical Progression

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease

Drug candidates in clinical trials for Alzheimer’s disease

Imaging endpoints for clinical trials in Alzheimer’s disease

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease

Predicting early Alzheimer’s with blood biomarkers and clinical features

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

Retinal tissue hypoperfusion in patients with clinical Alzheimer’s disease

Attitudes toward clinical trials across the Alzheimer’s disease spectrum

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Alzheimer’s Disease: Epidemiology and Clinical Progression

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease

Drug candidates in clinical trials for Alzheimer’s disease

Imaging endpoints for clinical trials in Alzheimer’s disease

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease

Predicting early Alzheimer’s with blood biomarkers and clinical features

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

Retinal tissue hypoperfusion in patients with clinical Alzheimer’s disease

Attitudes toward clinical trials across the Alzheimer’s disease spectrum

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Alzheimer’s Disease: Epidemiology and Clinical Progression

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease

Drug candidates in clinical trials for Alzheimer’s disease

Imaging endpoints for clinical trials in Alzheimer’s disease

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease

Predicting early Alzheimer’s with blood biomarkers and clinical features

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

Retinal tissue hypoperfusion in patients with clinical Alzheimer’s disease

Attitudes toward clinical trials across the Alzheimer’s disease spectrum

Related objects

Reset password